Nonalcoholic Fatty Liver Disease

Thrasher, Tyler; Abdelmalek, Manal F.

doi:10.18043/ncm.77.3.216

Cited by 6 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Многочисленные наблюдения указывают на связь НАЖБП и висцерального ожирения [12]. Патологическое ожирение в 95-100% случаев сочетается с развитием гепатоза и в 20-47% -НАСГ [13]. Это позволяет предположить, что не только ИР и ожирение играют роль в развитии НАЖБП.…”

Section: результаты и обсуждениеunclassified

The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease

Livzan

Ахмедов

Кролевец

et al. 2016

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

Section: результаты и обсуждениеunclassified

The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease

Livzan

Ахмедов

Кролевец

et al. 2016

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…Nowadays nonalcoholic fatty liver disease (NAFLD) is considered to be a multisystem disease that is primarily associated with components of the metabolic syndrome (MS) and is associated with cardiovascular and renal impairment [2,18]. Meanwhile, many questions about the mechanisms of chronic kidney disease (CKD) in patients with NAFLD remain unclear, especially in combination with hypertension (AH) [1,19]. The comorbidity of NAFLD with renoparenchymal arterial hypertension (RPAH) has not been sufficiently studied.…”

Section: Introductionmentioning

confidence: 99%

Contribution of adipoq genetic polymorphism to the formation and course of comorbidity of non-alcoholic fatty liver disease and renoparinchemal arterial hypertension

Babak

Prosolenko

Панченко

et al. 2021

View full text Add to dashboard Cite

Introduction. Nowadays nonalcoholic fatty liver disease (NAFLD) consider as multisystem disease that is primarily associated with components of the metabolic syndrome and is associated with cardiovascular and renal impairment. The comorbidity of NAFLD with renoparenchymal arterial hypertension (RPAH) has not been sufficiently studied. The purpose of the study was to investigate the influence of G276T genetic polymorphism of ADIPOQ on the severity of metabolic disorders, inflammation, liver, artery and kidney damage in the comorbidity of NAFLD and RPAH. Materials and methods. The study included 87 patients with comorbidity of NAFLD and RPAH, grade 2. The mean age of patients was 50.78 ± 9.35 years. The vast majority of patients were overweight or obese. The control group was composed of 20 healthy volunteers. Parameters of carbohydrate and lipid metabolism, liver and kidney’s function, adiponectin, fetuin-A, cytokeratin-18, pro-inflammatory cytokines levels were investigated. For diagnostic of non-alcoholic steatosis and indication parameters of arteries, an ultrasound method was used. Results. It was found that the T allele was detected in 62 (35.6%) patients of the main group, which was significantly (p<0,05) different from the control group (22.5%). In the presence of patients with comorbidity NAFLD and RPAH G/T and T/T genotypes, carbohydrate metabolism disorders are more pronounced than in the G/G genotype. Thus, index HOMA in this group was 4.52 ± 0.87, which was significantly higher than patients with G/G genotype - 3.77 ± 0.53 (p <0.01).The G276T polymorphism of the ADIPOQ is not associated with markers of liver and kidney damage in patients with NAFLD + RPAH. The presence of G/T and T/T genotypes in patients with comorbidity of NAFLD and RPAH is associated with an increase in interleukin-6 and fetuin-A compared to the G/G genotype. Patients with comorbidity of NAFLD + RPAH and with the T allele of the polymorphic marker G276T of the ADIPOQ gene are more likely to have impaired endothelium-dependent vasodilation, indicating more significant vascular reactivity disorders - 7.72 ± 1.25% for the genotype G/G, and 7.00 ± 1.10% for the genotype G/T (p <0,01). Conclusions. The presence of the T allele of the polymorphic marker G276T of the ADIPOQ is associated with the development of comorbidity of NAFLD and RPAH.

show abstract

“…This disorder is more common among patients who are obese and/or have diabetes mellitus, and NAFLD is on a trajectory to surpass HCV infection as the most common reason for liver transplantation in the United States [9]. In this issue, Tyler Thrasher and Manal Abdelmalek review this disorder and discuss the spectrum of disease ranging from simple steatosis (fatty liver), through the inflammation of nonalcoholic steatohepatitis (NASH), to cirrhosis and hepatocellular carcinoma [10]. As with many liver disorders, patients may have minimal or no symptoms until very advanced stages of the disease, and mild elevations in liver enzyme levels might be the only clue to the problem.…”

mentioning

confidence: 99%

State of the State in Gastroenterology

Muir¹

2016

North Carolina Medical Journal

View full text Add to dashboard Cite

Gastrointestinal disorders range from life-threatening conditions to benign disorders, but all can impact the daily life of millions of Americans. For colorectal cancer, liver disease, and other conditions, early identification is important to avoid late-stage presentations that carry the greatest mortality risk. The past decade has seen major advances in the development of biologic agents for treatment of inflammatory bowel disease and especially in the development of antivirals for treatment of hepatitis C infection. There is also better understanding of the role of diet in gastrointestinal disorders. New initiatives from research of benign disorders are expected in the next decade.

show abstract

Nonalcoholic Fatty Liver Disease

Cited by 6 publications

References 33 publications

The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease

The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease

Contribution of adipoq genetic polymorphism to the formation and course of comorbidity of non-alcoholic fatty liver disease and renoparinchemal arterial hypertension

State of the State in Gastroenterology

Contact Info

Product

Resources

About